If you're researching lung cancer, cell migration, or focal adhesion signaling, you have likely come across the gene PTK2 —and its famous protein product, FAK (Focal Adhesion Kinase) . But what exactly does PTK2 do? Why is it such a hot target in oncology research? And why should you consider using a PTK2 knockout cell line like the AhelixBio A549-PTK2KO for your experiments?
This blog post answers all these questions and provides a clear, beginner-friendly introduction to this powerful research tool.
PTK2 (Protein Tyrosine Kinase 2) is a human gene located on chromosome 8q24.3. It encodes the enzyme Focal Adhesion Kinase 1 (FAK) , a non-receptor tyrosine kinase that plays a central role in cellular communication.
| Basic Information | Detail |
|---|---|
| Gene Symbol | PTK2 |
| Full Name | Protein Tyrosine Kinase 2 |
| Protein Product | FAK (Focal Adhesion Kinase 1) |
| Molecular Weight | ~125 kDa |
| Chromosome Location | 8q24.3 |
| Number of Exons | 35 (multiple transcripts) |
| Key Domains | FERM domain, Kinase domain, FAT domain |
Think of FAK as a cellular signal integrator. It sits at the intersection of multiple pathways:
Integrin Signaling: FAK is activated when cells attach to the extracellular matrix (ECM). It tells the cell, "You are attached to something solid."
Growth Factor Signaling: FAK also responds to signals from growth factor receptors like EGFR, VEGFR, and PDGFR.
Cell Migration: FAK regulates the assembly and disassembly of focal adhesions, which are the "feet" cells use to crawl.
Cell Survival: FAK activates the PI3K/AKT pathway, which helps cells resist apoptosis (programmed cell death).
Simple Analogy: If a cell is a car, PTK2/FAK is the accelerator pedal for movement and growth. Push it, and the cell moves faster and grows more. Knock it out, and the cell essentially loses its ability to "drive."
A549 is a human lung adenocarcinoma epithelial cell line originally isolated from a 58-year-old Caucasian male with non-small cell lung cancer (NSCLC). It is one of the most widely used models for studying:
Lung cancer biology
Drug response and resistance
Epithelial-mesenchymal transition (EMT)
Inflammatory lung injury
Key genetic features of A549 cells:
KRAS G12S mutation (drives uncontrolled growth)
TP53 wild-type (functional p53)
STK11 (LKB1) mutation
| Research Area | Role of PTK2/FAK in A549 Cells |
|---|---|
| Tumor Growth | FAK promotes proliferation via the MAPK/ERK pathway |
| Metastasis | FAK is required for migration, invasion, and intravasation |
| Drug Resistance | High FAK activity correlates with resistance to chemotherapy and targeted therapy |
| Inflammation | FAK activates NF-κB in response to LPS (bacterial toxin) |
The Key Insight: Because A549 cells already harbor a KRAS mutation (a major driver of NSCLC), they are aggressively proliferative. Knocking out PTK2 allows researchers to ask: How much of this aggressive behavior depends on FAK?
If you want to study PTK2 function, you have several options. Here is how the AhelixBio CRISPR knockout compares to other approaches:
| Method | Duration of Effect | Completeness | Off-Target Risk | Best For |
|---|---|---|---|---|
| siRNA / shRNA | Transient (3–7 days) | Partial (70–90% knockdown) | Moderate | Quick validation, reversible studies |
| Chemical Inhibitor | Hours (reversible) | Partial (enzyme inhibition only) | Moderate (kinase selectivity) | Dose-response, time-course studies |
| CRISPR Knockout (AhelixBio) | Permanent | Complete (100% loss of protein) | Low (sequence-validated) | Long-term studies, in vivo work, mechanism studies |
Why Choose Knockout?
No need to re-transfect for every experiment
Eliminates variability between experiments
Allows for long-term studies (weeks to months)
Essential for in vivo xenograft studies
Q: Is PTK2 the same as PTK2B?
A: No. PTK2 (FAK) and PTK2B (PYK2) are different genes encoding distinct proteins. PTK2B is primarily expressed in neurons and hematopoietic cells, while PTK2 (FAK) is more ubiquitous. Do not confuse them in your experiments.
Q: Does PTK2 knockout kill A549 cells?
A: Generally, no. PTK2 knockout A549 cells remain viable and proliferate, though often at a reduced rate compared to wild-type. However, PTK2 is more critical for migration than for survival in most NSCLC lines.
Q: Can I use these cells for in vivo mouse studies?
A: Yes. Published studies have successfully used PTK2-KO A549 cells in NSG or nude mouse xenograft models. The knockout significantly reduces tumor growth and metastatic burden.
Q: How do I culture these cells?
A: Culture in F12K medium + 10% FBS at 37°C with 5% CO₂. Passage at 1:3 to 1:4 ratio when 80–90% confluent. Do not let them become overconfluent for extended periods.
Q: What is the difference between PTK2 knockout and PTK2 inhibition?
A: A knockout permanently removes the entire protein. An inhibitor (e.g., PF-562,271, defactinib) only blocks the kinase activity temporarily. Some FAK functions (scaffolding functions) are kinase-independent and will not be blocked by inhibitors—but will be blocked by knockout.
